-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B

Benzinga·07/30/2026 07:47:09
Listen to the news
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.